- Home
- BRY vs ATYR Comparison
BRY vs ATYR Comparison
Compare BRY & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- ATYR
- Stock Information
- Founded
- BRY 1909
- ATYR 2005
- Country
- BRY United States
- ATYR United States
- Employees
- BRY N/A
- ATYR N/A
- Industry
- BRY Oil & Gas Production
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRY Energy
- ATYR Health Care
- Exchange
- BRY Nasdaq
- ATYR Nasdaq
- Market Cap
- BRY 186.1M
- ATYR 451.3M
- IPO Year
- BRY N/A
- ATYR 2015
- Fundamental
- Price
- BRY $3.24
- ATYR $5.30
- Analyst Decision
- BRY Buy
- ATYR Strong Buy
- Analyst Count
- BRY 2
- ATYR 6
- Target Price
- BRY $5.00
- ATYR $20.20
- AVG Volume (30 Days)
- BRY 1.2M
- ATYR 3.7M
- Earning Date
- BRY 08-08-2025
- ATYR 08-12-2025
- Dividend Yield
- BRY 3.71%
- ATYR N/A
- EPS Growth
- BRY N/A
- ATYR N/A
- EPS
- BRY N/A
- ATYR N/A
- Revenue
- BRY $753,737,000.00
- ATYR N/A
- Revenue This Year
- BRY N/A
- ATYR $960.85
- Revenue Next Year
- BRY $0.96
- ATYR $1,283.47
- P/E Ratio
- BRY N/A
- ATYR N/A
- Revenue Growth
- BRY N/A
- ATYR N/A
- 52 Week Low
- BRY $2.11
- ATYR $1.58
- 52 Week High
- BRY $7.02
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- BRY 59.14
- ATYR 56.28
- Support Level
- BRY $3.13
- ATYR $5.07
- Resistance Level
- BRY $3.12
- ATYR $5.58
- Average True Range (ATR)
- BRY 0.17
- ATYR 0.39
- MACD
- BRY 0.02
- ATYR -0.04
- Stochastic Oscillator
- BRY 78.79
- ATYR 64.20
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.